Targeting Fibrosis

Redx is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicines for the treatment of fibrotic disease

Our Pipeline

Target/Product

Indications

Research

Preclinical

Phase 1

Phase 2

Status / Rights

Current programmes

Gl-restricted pan-ROCK Inhibitor
(RXC008)

Fibrostenotic Crohn’s Disease (FSCD)

Phase 2 FPFD expected
2026

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Idiopathic pulmonary fibrosis, Interstitial lung disease

Phase 2a data reported
2025

ROCK2 Selective Inhibitor
zelasudil (RXC007)

MASH, Cancer-associated fibrosis

Phase 1b/2 ready

Discoidin Domain Receptor (DDR)
Inhibitor program

Kidney, lung and liver fibrosis

IND/CTA submission expected
2027

DDR: Discoidin Domain Receptor; GI: Gastrointestinal; ROCK: Rho associated protein kinase

Current programmes

Gl-restricted pan-ROCK Inhibitor
(RXC008)

Phase 1

Fibrostenotic Crohn’s Disease (FSCD)

STATUS / RIGHTS

Phase 2 FPFD expected
2026

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Phase 2

Idiopathic pulmonary fibrosis, Interstitial lung disease

STATUS / RIGHTS

Phase 2a data reported
2025

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Phase 1

MASH, Cancer-associated fibrosis

STATUS / RIGHTS

Phase 1b/2 ready

Discoidin Domain Receptor (DDR)
Inhibitor program

Research

Kidney, lung and liver fibrosis

STATUS / RIGHTS

IND/CTA submission expected
2027

DDR: Discoidin Domain Receptor; GI: Gastrointestinal; ROCK: Rho associated protein kinase